Although early allograft dysfunction (EAD) negatively impacts survival from the first months following liver transplantation (LT), direct-acting antiviral agents (DAAs) have revolutionized hepatitis C virus (HCV) therapy. We investigated the EAD definition best predicting 90-day graft loss and identified EAD risk factors in HCV-positive recipients. From November 2002 to June 2016, 603 HCV-positive patients (hepatocellular carcinoma, 53.4%) underwent a first LT with HCV-negative donors. The median recipient Model for End-Stage Liver Disease (MELD) score was 15, and the median donor age was 63 years. At LT, 77 (12.8%) patients were HCV RNA negative; negativization was achieved and maintained by pre-LT antiviral therapy (61 patients) or pre-LT plus a pre-emptive post-LT course (16 patients); 60 (77.9%) patients received DAAs and 17 (22.1%) interferon. We compared 3 different EAD definitions: (1) bilirubin 10 mg/dL or international normalized ratio 1.6 on day 7 after LT or aspartate aminotransferase or alanine aminotransferase > 2000 IU/L within 7 days of LT; (2) bilirubin > 10 mg/dL on days 2-7 after LT; and (3) MELD 19 on day 5 after LT. EAD defined by MELD 19 on day 5 after LT had the lowest negative (0.1) and the highest positive (1.9) likelihood ratio to predict 90-day graft loss. At 90 days after LT, 9.2% of recipients with EAD lost their graft as opposed to 0.7% of those without EAD (P < 0.001). At multivariate analysis, considering variables available at LT, MELD at LT of >25 (OR 5 7.4) or 15-25 (OR 5 3.2), graft macrovesicular steatosis 30% (OR 5 6.7), HCV RNA positive at LT (OR 5 2.7), donor age > 70 years (OR 5 2.0), earlier LT era (OR 5 1.8), and cold ischemia time 8 hours (OR 5 1.8) were significant risk factors for EAD. In conclusion, in HCV-positive patients, MELD 19 on day 5 after LT best predicts 90-day graft loss. Preventing graft infection by pre-/peri-LT antiviral therapy reduces EAD incidence and could be most beneficial in high-MELD patients and recipients of suboptimal grafts.
Hepatitis C virus (HCV) is the main cause of cirrhosis and hepatocellular carcinoma (HCC) and still represents the most common indication for liver transplantation (LT) in Europe and United States.
(1) Although infection almost universally recurs in patients who are viremic at LT, (2) the recent advent of safe and effective direct-acting antiviral agents (DAAs) has revolutionized HCV therapy. Yet the debate about the best time for treating the infection in the transplant setting is still open. (3) (4) (5) On the one hand, pre-LT eradication is aimed at improving liver function and delisting some patients (an appropriate strategy in the current context of organ shortage), (6) and at preventing graft infection, thus facilitating post-LT management. (7) This approach could be particularly appropriate in areas where median donor age has come to exceed 60 years, thus leading to a more severe HCV recurrence. (8) On the other hand, unpredictable waiting time, antiviral therapy duration, risk of patient death, and/or tumor progression on the list, and higher rates of sustained virological response in transplant recipients compared with patients with decompensated cirrhosis, incline clinicians to treat infection after LT, generally starting 3 months after LT, as suggested in the last update of the European Association for the Study of the Liver recommendations. (3) It is unlikely that clinical trials to prospectively compare these 2 different approaches will be feasible because they would have to recruit a prohibitively large number of patients and extend over an exceedingly long time. (5) In the last 2 decades, the transplant community has increased its efforts to expand the donor pool by using so-called "extended criteria donors" in order to circumvent donor organ shortage. A consequence of this policy has been an increased incidence of poor graft function immediately after transplant. (9) Early allograft dysfunction (EAD) in LT recipients adversely affects graft and patient survival, starting from the very first months after LT, and may lead to extrahepatic organ dysfunction, especially kidney impairment. (10) Various definitions of EAD have been put forward in order to identify those LT recipients who are at risk for graft loss within 90-180 days from LT, such as the following:
1. The definition from Olthoff et al.: total bilirubin level 10 mg/dL or international normalized ratio (INR) 1.6 on postoperative day 7 or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level > 2000 IU/L within the first 7 days. (11) 2. The definition from Deschênes et al.: peak total bilirubin level > 10 mg/dL on postoperative days 2-7. (12) 3. The definition from Wagener et al.: Model for End-Stage Liver Disease (MELD) score higher than 18.9 on postoperative day 5.
Donor age > 45 years, recipient MELD score at LT, donor body mass index, degree of graft macrovesicular steatosis, cold ischemia time, and HCV infection have been reported as significant risk factors for EAD, (11, 14, 15) but until now, no study has either focused solely on the HCV-positive population, or, more relevantly, has investigated the potential impact of HCV RNA status at transplant on EAD incidence.
This retrospective single-center study was performed on a series of HCV-positive first LT recipients, with the following aims:
1. To establish, among the known EAD definitions, which one best predicted graft loss within 90 days of LT. 2. To assess EAD impact on 90-day graft and patient survival. 3. To identify independent risk factors for EAD in this population.
We intended to generate new data relevant to optimizing early outcomes of HCV-positive LT recipients in the current era of persisting organ shortage but extraordinarily effective DAAs.
Patients and Methods

STUDY POPULATION
From November 2002 to June 2016, 1706 first LTs were performed at the Liver Transplant Center of Turin, Italy. In this study, we enrolled 603 consecutive adult HCV-positive patients with cirrhosis who underwent a first LT with grafts from HCV-negative, brain dead heart-beating donors. All livers were preserved with conventional static cold storage.
Informed consent was signed by all patients upon entering the waiting list. Because of the retrospective design, no specific approval was sought from the local institutional ethics committee. By Italian law, Regional Transplantation Centers are the custodians of donor/recipient biomedical data also for research purposes. All study procedures 
DATA COLLECTION
Variables collected in the study population and in their donors are shown in Table 1 .
The pattern and degree of fatty infiltration of the graft were assessed on liver biopsies routinely obtained at the time of transplant surgery, before closing the abdomen.
Total bilirubin, INR, AST, ALT, and serum creatinine were assessed at LT and daily after surgery, up to day 7.
Laboratory MELD was calculated at LT and on day 5 after transplant. Mortality or retransplantation within 90 days were recorded and survival data were collected up to December 31, 2016.
HCV TESTING
Antibodies to HCV were detected by the Architect assay (Abbott Laboratories, Abbott Park, IL). HCV RNA was detected until April 2007 by signal amplification Branched-DNA test (Versant HCV, version 3.0, Bayer Diagnostic Corporation, Tarrytown, NY; range of quantitation from 61.5 3 10 to 7.7 3 10 6 IU/ mL); after April 2007, by the automated highsensitivity system COBAS AmpliPrep/COBAS TaqMan HCV, version 1 (Roche Molecular Systems Inc., range of quantitation from 4.3 3 10 to 6.9 3 10 7 IU/ mL); after October 2012, by version 2 of the AmpliPrep/COBAS TaqMan HCV test (range of quantitation from 1.5 3 10 to 1.0 3 10 8 IU/mL).
CLINICAL PROTOCOL
Immunosuppression was based on calcineurin inhibitors (cyclosporine or tacrolimus), antimetabolites and steroids (tapered to suspension in 6 months). Moderate/severe acute rejection episodes were treated with high-dose methylprednisolone boluses on 3 consecutive days; monoclonal anti-CD3 antibodies were used in steroid-resistant rejection. Until May 2014, anti-HCV therapy before LT was based on ribavirin and peginterferon-a 6 first generation protease inhibitors and was practicable only in a few patients with well-compensated cirrhosis affected by HCC. Since June 2014, DAAs plus ribavirin were used in all patients listed for LT with a MELD score below 25, a creatinine clearance 30 mL/minute, and an expected time on the waiting list of at least 3 months. Patients who had received DAAs before LT and were HCV RNA negative for fewer than 30 days at the time of LT continued antiviral therapy immediately after LT for at least 12 weeks in order to consolidate HCV RNA negativization. (16, 17) STUDY OUTCOME MEASURE Graft loss within 90 days of transplant, defined as mortality or retransplantation, was the study outcome measure.
STUDY ENDPOINT AND OBJECTIVES
EAD was the study endpoint, and it was investigated with 3 objectives:
1. To establish which EAD definition best predicted graft loss within 90 days of transplant. For this purpose, we compared the 3 previously published EAD definitions:
a. Total bilirubin 10 mg/dL or INR 1.6 on postoperative day 7 or AST or ALT > 2000 IU/L within the first 7 days. (11) b. Peak total bilirubin > 10 mg/dL on postoperative days 2-7. (12) c. MELD score > 19 on postoperative day 5.
2. To assess EAD impact on 90-day graft and patient survival. 3. To identify EAD independent risk factors.
STATISTICAL ANALYSIS
Categorical variables were reported as n (%), and quantitative variables were shown as median (interquartile range [IQR] ).
Receiver operating characteristic curve was plotted, and the point on the curve closest to the upper left corner was considered the best cutoff value of MELD score on day 5 after transplant to predict 90-day graft loss. Positive and negative likelihood ratios were calculated for each EAD definition. Kaplan-Meier analysis was performed to evaluate the effect of EAD on graft survival, and survival curves were compared using the log-rank test. Univariate analyses were carried out using chi-square test for categorical variables and Mann-Whitney U test for continuous variables.
To obtain a parsimonious set of EAD predictors, recipient and donor variables available at LT were selected based on the background knowledge. The variables were fitted into a logistic regression model, and a stepwise backward elimination was used. Odds ratio (OR) and 95% confidence interval (CI) were reported. Data elaboration was performed using R software (version 3.3.1, R Project for Statistical Computing).
Results
Of the 603 enrolled patients, a majority were males (80.8%). Of the patients, 10.2% were affected by HCV genotype 1a; 62.2% were affected by HCV genotype 1b; 7.4% were affected by HCV genotype 2; 13.9% were affected by HCV genotype 3; and 6.3% were affected by HCV genotype 4. A total of 53.4% of the patients were affected by HCC, and the median MELD score at LT was 15. A total of 77 patients (9.5% HCV genotype 1a; 56.8% HCV genotype 1b; 5.4% HCV genotype 2; 21.6% HCV genotype 3; and 6.7% HCV genotype 4) were HCV RNA negative at LT: 17 (22.1%) received peginterferon-a and ribavirin, and 60 (77.9%) received DAAs plus ribavirin before LT. Sixteen patients bridged DAAs from before to after LT for at least 12 weeks to maintain HCV RNA negativization. Two patients who tested HCV RNA negative at the first post-LT week relapsed at weeks 7 and 5 after LT: the first one affected by HCV genotype 1b was treated until LT with peginterferon-a plus ribavirin for 24 weeks, whereas the second one, affected by genotype 4, received sofosbuvir plus ribavirin for 141 days before LT. Both patients had been HCV RNA negative at LT for at least 30 days and stopped antiviral therapy at LT. The median donor age was 63.0 years, with one-third of the donors being older than 70 years old. The median donor risk index was 1.8, and 3.0% of the grafts showed a macrovesicular steatosis 30% (Table 1 ). Supporting Table 1 shows the clinical and demographic characteristics of donors and recipients according to HCC diagnosis.
Supporting Fig. 1 depicts the trend of bilirubin, INR, and creatinine during the first 7 days after LT. The rate of primary nonfunction was 1.0% (6/603). Two patients lost their graft on day 1; 2 lost the graft on day 4; 1 lost the graft on day 5; and 1 lost the graft on day 7 after surgery. They all underwent re-LT. According to the receiver operating characteristic curve, the best cutoff of MELD score on posttransplant day 5 to predict 90-day graft loss was 18.5 (area under the curve, 0.8; 95% CI, 0.7-0.8; Supporting Fig. 2 ).
Comparison of Different EAD Definitions
We evaluated the risk of EAD occurrence according to 3 different definitions: Of the 3 definitions, a MELD score 19 on day 5 after surgery showed the highest positive likelihood ratio (1.9) and the lowest negative likelihood ratio (0.1) in predicting 90-day graft loss (Table 2 ). This EAD definition satisfied the first study objective and was used for subsequent analyses.
THE 90-DAY GRAFT AND PATIENT SURVIVAL
A total of 35 out of 603 (5.8%) patients lost their graft within 90 days after surgery due to graft complications (6 primary nonfunction, 12 delayed nonfunction, 2 hepatic artery thrombosis, 1 biliary complication, 1 acute rejection, and 1 hepatic veno-occlusive disease), infection and multiorgan failure (9 patients), HCV recurrence (2 patients), and cardiac failure (1 patient). A total of 20 patients (3.3%) with graft complications underwent re-LT, whereas 18 (3.0%) patients died within 90 days of LT ( Table 1) .
The occurrence of EAD significantly worsened the 90-day graft (90.8% versus 99.3%; P < 0.001) and patient (94.9% versus 99.6%; P < 0.001) survival rates (Fig. 1A,B) . Table 3 shows the association of clinical factors with EAD at univariate analysis.
RISK FACTORS FOR EAD
The rates of HCC and of HCV RNA negativity were significantly higher in the non-EAD group. On the other hand, MELD at LT, donor age 3 recipient MELD, donor risk index, cold ischemia time, and in-hospital stay were significantly reduced in the non-EAD group compared with the EAD group.
To account for the changes in transplant care and performance which occurred over time, we compared the first half (November 2002 to March 2009; n 5 300) with the second (April 2009 to June 2016; n 5 299) half of the patients enrolled in the study. The EAD rate decreased from 61.3% in the earlier era to 43.5% in the more recent one (P < 0.001). The latter era was characterized by a significant increase in donor age and incidence of graft macrovesicular steatosis 30%. However, the cold ischemia time duration and the proportion of hepatitis B core antibody (HBcAb)-positive grafts were lower, and the rates of HCC and HCV RNA-negative patients at LT were higher (Supporting Table 2 ). Table 1 depicts HCV RNA-negative patients compared with positive ones, showing a significantly higher rate of HCC and a lower MELD score at LT. Median donor age and the rate of graft macrovesicular steatosis 30% were significantly higher in the HCV RNA-negative group. Table 4 summarizes the results of the multivariate logistic regression performed on a set of recipient and donor features available at LT. All variables significantly associated with EAD at univariate analysis were included, except for the donor risk index which was replaced by donor age due to its well-known detrimental effect on LT outcomes in HCV-positive recipients. We forced into the analysis also graft macrovesicular steatosis 30% because we observed that 4 such livers were lost within day 4 after transplant and were consequently missed by EAD defined as MELD 19 on day 5.
A MELD score at LT > 25 (OR 5 7.4), graft macrovesicular steatosis 30% (OR 5 6.7), a MELD score at LT between 15 and 25 (OR 5 3.2), HCV RNA positivity at LT (OR 5 2.7), donor age > 70 years (OR 5 2.0), earlier transplant era (OR 5 1.8), and a cold ischemia time 8 hours (OR 5 1.8) were independent predictors of EAD.
HCV RNA-positive status at LT was an independent predictor of EAD also when the analysis was restricted to the more recent era (OR 5 2.7; Supporting Table 3 ).
In the 193 patients who received a liver graft older than 70 years, EAD occurred in 61.5% (99/161) of HCV RNA-positive recipients as opposed to 21.9% (7/32) of HCV RNA-negative recipients (P < 0.001).
Discussion
We studied a series of more than 600 HCV-positive recipients consecutively transplanted from HCVnegative donors and found a significant impact of HCV RNA status at transplant on the incidence of early graft dysfunction.
The advent of DAAs has revolutionized anti-HCV therapy, especially in the LT setting. Indeed, their remarkably good safety profile allows treating patients either before or after LT, so a heated controversy on the optimal timing for treatment is going on. (3) (4) (5) According to a recent decision analytical simulation model of 10,000 patients with Child B and C cirrhosis, treatment before LT seems to be the most cost-effective strategy for patients with decompensated cirrhosis and MELD > 13. (18) Furthermore, a European multicenter study showed that DAAs may lead to a remarkable clinical improvement and organ salvage because 19.2% of the patients treated while on the transplant waiting list were delisted at 60 weeks from the beginning of antiviral therapy. (6) Finally, prevention of graft HCV infection simplifies post-LT patient management. Nevertheless, lower rates of virological response in patients with decompensated cirrhosis compared with post-LT recipients and unpredictable waiting time on the LT list can lead clinicians to prefer the post-LT approach, especially for patients with MELD >18-20, where data on the efficacy of the new treatments are scanty. (19) (20) (21) (22) (23) As an interesting alternative, the results of a very short pre-emptive antiviral strategy have recently been published. Sixteen patients received sofosbuvir plus ledipasvir 1 day before and 4 weeks after LT: 37.5% of the patients showed an HCV RNA inferior to 15 IU/mL on day 7 after LT, and the rate of sustained virological rate at 12 weeks was 87.5%. (24) At present, in order to meet the growing LT demand and the persistent organ shortage, the transplant community is using more and more suboptimal grafts, which are associated with an increased risk of initial poor function and early graft failure. For this reason, in this exciting era of powerful DAAs, we focused on the HCV-positive recipients and investigated whether avoiding HCV reinfection at the time of reperfusion could have beneficial effects on the early functional recovery of the graft. With this aim, we studied EAD, a well-known predictor of early graft loss in the transplant population. (11) (12) (13) We compared 3 different previously established EAD definitions: More than half of our HCV patients experienced EAD by every definition used, against a significantly lower rate in our non-HCV patients (approximately 45%, unpublished data). Exclusive HCV etiology and high donor risk index in this study cohort can explain a higher rate of EAD than that reported in other cohorts (which enrolled patients with end-stage liver disease of any etiology); nevertheless, our patients showed good 90-day graft and patient survival rates. (11, 13, 14) Similar to what was reported by Wagener et al. (13) on 572 LT recipients (half of them infected by HCV), we found that a MELD score 19 on day 5 after transplant was the best predictor of 90-day graft loss; 9.2% of EAD patients in our cohort and 17.0% in the American cohort lost their graft within 90 days of transplantation, against 0.7% and 2.0%, respectively, of non-EAD patients.
Looking at predictors of EAD in our cohort, MELD score at LT, moderate/severe macrovesicular steatosis, and advanced donor age exerted a negative impact, as expected. In addition, we confirmed the protective effect of a cold ischemia time shorter than 8 hours, a practice adopted in recent years in response to an increasing donor age. Yet, the most intriguing finding of our study was the significantly reduced OR for EAD in patients who were HCV RNA negative at LT; this finding was confirmed also when the analysis was restricted to the more recent era. Notably, HCV RNA-negative patients, compared with positive ones, showed a significantly higher rate of HCC and, as a consequence, a lower MELD score at LT. However, median donor age and the rate of graft macrovesicular steatosis 30% were significantly higher in the negative group.
Ischemia/reperfusion injury is recognized as the main culprit of initial poor graft function. It causes infiltration of polymorphonuclear and T cells, activation of endothelial and Kupffer cells, and formation of reactive oxygen species, all leading to hepatocyte injury through inflammation and cytotoxicity. (25) GarciaRetortillo et al. (26) published a detailed study 15 years ago on early post-LT HCV kinetics. The Spanish study showed in 20 patients that HCV RNA-circulating levels decrease not only during the anhepatic phase, but also during the first 12-24 hours, presumably as a consequence of an uptake of the virus by the hepatocytes and/or the hepatic reticuloendothelial system. Furthermore, 12 of the 13 patients who were on steroid immunosuppression experienced a persistent increase in HCV RNA in the first week. Likewise, Fukumoto et al. (27) showed in 8 of 9 patients who received steroids, azathioprine, and a calcineurin inhibitor, that HCV RNA levels increased after the second postoperative day, probably as an expression of active viral synthesis, the immunosuppression regimen being the most important determinant of early viral kinetics. (28) Even if sequential histological evaluations were not available in the first days after LT in our patients, we can speculate that the uptake and replication of the virus in the hepatocytes immediately after LT may interfere with the physiological process of regeneration and functional recovery after ischemia/reperfusion injury.
Lastly, it should be noted that the very low EAD incidence we recorded in HCV RNA-negative recipients of grafts older than 70 years provides a new argument against the previously recommended judicious use of advanced age donors in HCV recipients. (29) In this fashion, pre-or peri-LT viral eradication could not only improve early LT outcomes but also increase LT opportunities for HCV-positive candidates, especially in countries relying mostly on elderly donors.
Although further data on the safety and efficacy of DAAs in severely decompensated patients are eagerly awaited, our findings evidence a so-far unrecognized benefit of preventing graft reinfection, thus giving new relevance to the transplant hepatologists' attempt at achieving HCV RNA negativization before transplant even in very sick patients.
We acknowledge that this retrospective singlecenter study is limited by the long time needed to recruit an adequate number of patients and the possible effects of changes in transplant care and performance occurring over time. For this reason, we stratified our data by transplant era, comparing the first with the second half of the study period when the EAD rate was significantly reduced despite a worse donor risk profile. In a multivariate analysis, as expected, an earlier transplant era emerged as an independent predictor of EAD, but this did not invalidate the significant role of the recipient HCV RNA positivity as an EAD risk factor.
In conclusion, HCV-positive recipients presenting a MELD score 19 on day 5 after LT are at an increased risk of graft loss within 90 days of transplantation. Our data suggest that negativization of viremia by pre-LT antiviral therapy not only prevents graft infection at reperfusion, but also reduces EAD incidence. This therapeutic strategy should be further investigated for its potential to improve early survival, especially in high MELD patients and in recipients of grafts of suboptimal quality due to macrosteatosis or advanced donor age.
